Navigation Links
Rexinoid Developed by NuRx Pharmaceuticals Shows Promise in Prevention, Treatment of Lung, Breast Cancer, Paper in Clinical Cancer Research Reports
Date:3/26/2008

ents currently approved for these indications."

NuRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development of next-generation retinoid and rexinoid compounds for application in oncology (treatment, prevention and adjunctive supportive therapy) and other highly prevalent diseases. The company's lead compounds are NRX4204, a highly specific, next-generation rexinoid agonist that is targeted for development in non-small cell lung carcinoma and breast cancer and a RAR agonist for the treatment of acute leukemia. Based in Irvine, Calif., NuRx has a technology and IP platform that includes a library of nearly 6,000 compounds supported by 230 issued U.S. and international patents and more than 80 additional patents in application. For more information, visit http://www.nurxpharmaceutical.com.

The above information contains information relating to the Company that is based on the beliefs of the Company and/or its management as well as assumptions made by and information currently available to the Company or its management. The Company, from time to time, may discuss forward-looking information. Except for the historical information contained in this news release, all forward-looking statements are predictions by the Company's management and are subject to various risks and uncertainties that may cause results to differ from management's current expectations. Such factors include the fact that the Company is engaged in early stage research and does not expect to obtain any revenues for several years and other risks as detailed from time to time in the Company's registration statement and reports and filings with the Securities and Exchange Commission. All forward-looking statements, if any, in this news release represent the Company's judgment as of the date of this news release. The Company disclaims, however, any intent or obligation to update forward-lookin
'/>"/>

SOURCE NuRx Pharmaceutical Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. New Data Confirms That a Selective, Fully Human Anti-VEGF Antibody Being Developed by Peregrine is as Effective as Avastin(R) in Preclinical Cancer Models
2. Anacor Pharmaceuticals Announces Positive Results from Phase 2a Clinical Trial of AN2728 in Psoriasis Patients
3. NuRx Pharmaceuticals Doses First Patient in Phase I Clinical Trial of First-in-Class RXR Agonist NRX4204
4. MAP Pharmaceuticals Reports Positive Results From Comparative Pharmacokinetic Trial for its Pediatric Asthma Product Candidate
5. VIA Pharmaceuticals Completes Enrollment In Phase 2 Carotid Endarterectomy (CEA) Trial
6. Poniard Pharmaceuticals Announces Clinical Data From Picoplatin Oral Phase 1 to Be Presented at the American Association of Cancer Research Annual Meeting
7. BioNumerik Pharmaceuticals and ASKA Pharmaceutical Co. Announce Results from Phase III Clinical Trial of Tavocept(TM)
8. Merrimack Pharmaceuticals Completes Enrollment in a Phase 2 Study of MM-093 in Patients with Rheumatoid Arthritis
9. Access Pharmaceuticals to Conduct Conference Call to Update Financial Community
10. Sunesis Pharmaceuticals Reports Positive Interim Data for SNS-595 Single-Agent Activity in Platinum-Resistant Ovarian Cancer
11. Keryx Biopharmaceuticals Announces that the SUN-MICRO Phase 3 Clinical Trial Failed to Meet its Primary Efficacy Endpoint
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... , July 11, 2014  Australian drug delivery ... that it has raised A$19.3 million via a placement ... Europe , the U.S., Asia ... million from a share purchase plan (SPP) to be ... will be made in two tranches. "This ...
(Date:7/11/2014)... July 11, 2014 According to ... "Endoscopy Devices Market (Endoscopes, Endoscopic Operative Devices, and Visualization ... and Forecast, 2013-2019" the global endoscopy devices market was ... expected to grow at a CAGR of 6.8% from ... USD 36.9 billion in 2019. Browse the ...
(Date:7/11/2014)... , July 11, 2014  Veran Medical ... announced today the positive, cost-effective final results ... SPiNPerc™ procedure. The SPiNPerc endobronchial percutaneous biopsy ... percutaneous approach to biopsy when a traditional ... and physicians experience positive financial outcomes when ...
Breaking Medicine Technology:Phosphagenics' A$19.3 million Capital Raising 2Phosphagenics' A$19.3 million Capital Raising 3Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 2Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 3Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 4Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 5Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 6Veran Medical Publishes Lung Cancer Patient Management Study 2
(Date:7/14/2014)... ATLANTA July 14, 2014 Physical fitness may buffer ... sitting, according to a new study by researchers from ... University of Texas. The study appears in the journal ... between prolonged sedentary time and obesity and blood markers ... taking fitness into account. , Sedentary behavior has been ...
(Date:7/14/2014)... Wisconsin (PRWEB) July 14, 2014 Secure ... software security, is partnering with the Software Assurance Marketplace ... to improve the software that drives everyday life. , ... institutions and housed in the Morgridge Institute for Research, ... S&T to advance software security practices by building a ...
(Date:7/14/2014)... Eye tests could be used to identify people in ... suggest. In one study, early results from 40 ... significant association between levels of beta-amyloid plaques in the ... in the brain. Beta-amyloid plaques in the brain are ... test could be used in conjunction with the brain ...
(Date:7/14/2014)... HealthDay Reporter MONDAY, July 14, ... to multiple health issues, but dementia isn,t one of them, ... may even delay dementia, the researchers found. "For those ... associated with a later age of developing full-blown dementia compared ... Woodruff. Woodruff, an assistant professor of neurology at ...
(Date:7/14/2014)... KeyPoint Credit Union is teaming up with ... and one-mile family fun walk. The run begins inside ... finishes inside Levi’s® Stadium. , Over the past five ... Mission City Community Fund. All proceeds benefit education, seniors ... athletes, part-time pavement-pounders and walkers are invited to help ...
Breaking Medicine News(10 mins):Health News:Physical fitness associated with less pronounced effect of sedentary behavior 2Health News:Madison-based SWAMP, Secure Decisions partner to enhance software security 2Health News:Madison-based SWAMP, Secure Decisions partner to enhance software security 3Health News:Eye Tests Might Help ID Alzheimer's, Studies Suggest 2Health News:Widowhood May Delay Dementia in Some Seniors, Study Finds 2Health News:Widowhood May Delay Dementia in Some Seniors, Study Finds 3
... 20 Conseco, Inc. (NYSE: CNO ),today ... rights plan,designed to protect stockholder value by preserving the ... operating loss carryforwards under,Section 382 of the Internal Revenue ... tax assets upon an "ownership change." The rights ...
... study found , , TUESDAY, Jan. 20 (HealthDay News) -- ... exercise, say U.S. researchers. , Dr. Jasmine Grewal, ... with abnormal diastolic function (when the heart is relaxed ... lower maximum capacity for exercise. The left ventricle is ...
... who purchased raw milk from the Conestoga Valley Dairy ... due to the risk of Salmonella contamination, Agriculture Secretary ... pasteurized to kill disease-causing bacteria or homogenized. Pennsylvania farms ... product samples tested in a laboratory due to the ...
... WASHINGTON, Jan. 20 While the U.S. Food and Drug ... affected by last week,s Peanut Corporation of America (PCA) recall ... that national brands of jarred peanut butter are not affected ... ingredients from PCA. , , In addition, ...
... Host Five Cancer Fighters on January 30th for a ... Lillians(TM), The Hippest Shoppe in Town(R) and the ... it will postpone "the dance," its annual fundraising event ... Oct. 23, 2009, at the Medina Entertainment Center.The annual ...
... entails lower risk, speedier recovery, researchers say , , TUESDAY, ... accessing and treating ailing hearts with angioplasty may be ... catheterization technique reduces risk, bleeding, cost and patient recovery ... year, about one million Americans undergo angioplasty to open ...
Cached Medicine News:Health News:Conseco Adopts Stockholder Rights Plan 2Health News:Conseco Adopts Stockholder Rights Plan 3Health News:Conseco Adopts Stockholder Rights Plan 4Health News:Conseco Adopts Stockholder Rights Plan 5Health News:Lillians(TM) Postpones 'The Dance' Fundraising Event; New Date Is October 23, 2009 2Health News:Angioplasty Via Wrist May Be Safer 2
MediNotes e is an EMR design which utilizes a "tab concept for navigation. MediNotes e can display multiple patients, encounter notes, workflow items, patient flow, messages, alerts, and more, all in...
... Pro Software developed a touchscreen EHR and ... While a user can choose to use ... to maintain eye contact while recording encounter ... Pro EHR also runs on a pen ...
... Anasazi Clinicians HomePage is a comprehensive on-line ... helps you by reducing your time and ... to concentrate on the clients quality of ... completes a chart audit and shows you ...
... The GE RecordsTFC System ... Registration and other patient/resident record ... approach. It supports multiple facilities ... outpatient and ambulatory clinics, community ...
Medicine Products: